|
Clinical Studies Download Abstracts of Oral Cancer Clinical Studies ViziLite® Plus with TBlue® is a clinically proven oral cancer screening system that has been helping oral healthcare professionals identify and mark suspicious lesions for more than a decade. This system uses a chemiluminescent light source and a patented, GMP manufactured toluidine blue dye called TBlue®. TBlue® provides the deep blue staining that allows ViziLite® Plus-identified lesions to be seen clearly under normal light. ViziLite® and ViziLite® Plus with TBlue® have had numerous clinical studies published supporting its ability to help oral healthcare professionals identify, evaluate, monitor and mark abnormal oral lesions suspicious for pathology including precancerous cells and cancer that may be difficult to see during a regular visual exam.
To visit any of the web sites listed below copy the link and paste in the address field of a web browser. Epstein JB, Silverman S Jr, Epstein JD, et al. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol. 2008;44(6):615. Kerr AR, Sirois DA, Epstein JB. Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. New York University College of Dentistry. J Clin Dent. 2006;17(3):59-63. Huber MA, Bsoul SA, Terezhalmy GT. Acetic acid wash and chemiluminescent illumination as an adjunct to conventional oral soft tissue examination for the detection of dysplasia: a pilot study. University of Texas Health Science Center of San Antonio. Quintessence Int. 2004;35(5):378-84. Epstein JB, Gorsky M, Lonky S, et al. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. College of Dentistry and Illinois Cancer Center. Spec Care Dentist. 2006;26(4):171-4. Ram S, Siar CH. Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. Int J Oral Maxillofac Surg. 2005;34(5):521-7. Zhang L, Williams M, Poh CF, et al. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. University of British Columbia. Cancer Res. 2005;65(17):8017-21. |
 |
Site Map | Privacy and Terms of Use | Warranty Information | Return Policy | Contact Us | TOLMAR © 2012 Zila Inc. ATRIDOX® and ATRISORB® are registered trademarks and FreeFlow™ is a trademark of TOLMAR Inc. All other ® and ™ indicate trademarks of Zila, Inc. and its subsidiaries. All Rights Reserved |
 |